4.7 Article

Addressing the Complexity of Chronic Obstructive Pulmonary Disease From Phenotypes and Biomarkers to Scale-Free Networks, Systems Biology, and P4 Medicine

Journal

Publisher

AMER THORACIC SOC
DOI: 10.1164/rccm.201009-1414PP

Keywords

inflammation; genetics; networks; systems biology

Funding

  1. FIS [PI09/00629]
  2. Almirall
  3. GSK
  4. AstraZeneca
  5. Boehringer-Ingelheim
  6. Pfizer
  7. Aeris
  8. Forrest

Ask authors/readers for more resources

Chronic obstructive pulmonary disease (COPD) is a complex disease at the clinical, cellular, and molecular levels. However, its diagnosis, assessment, and therapeutic management are based almost exclusively on the severity of airflow limitation. A better understanding of the multiple dimensions of COPD and its relationship to other diseases is very relevant and of high current interest. Recent theoretical (scale-free networks), technological (high-throughput technology, biocomputing), and analytical improvements (systems biology) provide tools capable of addressing the complexity of COPD. The information obtained from the integrated use of those techniques will be eventually incorporated into routine clinical practice. This review summarizes our current knowledge in this area and offers an insight into the elements needed to progress toward an integrated, multilevel view of COPD based on the novel scientific strategy of systems biology and its potential clinical derivative, P4 medicine (Personalized, Predictive, Preventive, and Participatory).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available